Amicus Therapeutics

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024

Retrieved on: 
Friday, March 1, 2024

PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March.

Key Points: 
  • PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March.
  • Cowen 44th Annual Health Care Conference in Boston, MA, on Monday, March 4, 2024, at 11:10 a.m. E.T.
  • Leerink Partners 2024 Global Biopharma Conference in Miami, FL on Monday, March 11, 2024, at 3:20 p.m. E.T.

Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates

Retrieved on: 
Wednesday, February 28, 2024

At the end of 2023, there were >2,400 people living with Fabry disease on Galafold following a year of increased demand.

Key Points: 
  • At the end of 2023, there were >2,400 people living with Fabry disease on Galafold following a year of increased demand.
  • Eleven posters and an oral presentation highlighting Amicus’ development programs in Fabry disease and Pompe disease presented at the 20th Annual WORLDSymposium™.
  • ET to discuss the full-year 2023 financial results and corporate updates.
  • A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com .

In Sickness. Men and the Culture of Caregiving Launches as Podcast Sharing Powerful Stories of Male Caregivers

Retrieved on: 
Thursday, February 29, 2024

Episode 1 features the incredible story of John F. Crowley, former Genzyme executive, Amicus Therapeutics founding CEO and Executive Chairman, and incoming CEO of BIO. Crowley is best known for his role as an entrepreneur in the biotechnology industry following the 1998 diagnosis of his two youngest children with Pompe disease, a rare and often fatal neuromuscular disorder. His children’s diagnosis inspired him to co-found a biotech company to develop a treatment that he credits with ultimately saving his children’s lives. The Crowley family journey was chronicled in the book “The Cure: How a Father Raised $100 Million--and Bucked the Medical Establishment--in a Quest to Save His Children” by Geeta Anand and also depicted in the major motion picture “Extraordinary Measures” starring Harrison Ford, Brendan Fraser and Keri Russell.

Key Points: 
  • Episode 1 features the incredible story of John F. Crowley , former Genzyme executive, Amicus Therapeutics founding CEO and Executive Chairman, and incoming CEO of BIO.
  • Men and the Culture of Caregiving will focus mostly on stories of male caregivers who have supported individuals with various diseases and medical conditions across all therapeutic areas including select cancers, ALS, Alzheimer’s, and numerous rare diseases.
  • “As more men are identifying themselves as caregivers for their loved ones, it’s great there will be an avenue, like this podcast, for male caregivers to share their experiences,” said Marvell Adams, Jr. CEO, Caregiver Action Network.
  • “We are looking forward to hearing what these caregivers have to say—as they continue to amplify the needs of the over 90 million caregivers in the US."

Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024

Retrieved on: 
Thursday, February 15, 2024

PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 28, 2024, at 8:30 a.m.

Key Points: 
  • PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 28, 2024, at 8:30 a.m.
  • ET to discuss financial results for the full-year ended December 31, 2023.
  • Participants and investors interested in accessing the call by phone will need to register using the online registration form .
  • A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com .

A Collaborative Approach to Advancing Access and Equity in Rare Disease Clinical Trials, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, February 13, 2024

TORONTO, Feb. 13, 2024 /PRNewswire-PRWeb/ -- Ensuring that all patients have equal access to participate in clinical trials across all geographies has become essential throughout the industry. Patient recruitment and retention remain one of the most challenging hurdles in clinical development, particularly for rare diseases. Implementing a patient-focused clinical trial design and fostering a collaborative approach between the Sponsor, CRO, sites, and advocacy groups can help lead to successful clinical trials.

Key Points: 
  • The featured speakers will discuss how to engage and support patients in rare disease clinical trials.
  • Implementing a patient-focused clinical trial design and fostering a collaborative approach between the Sponsor, CRO, sites, and advocacy groups can help lead to successful clinical trials.
  • In this webinar, Medpace , a global full-service CRO, will discuss the importance of equity in patient-friendly rare disease trials.
  • Register now for the Rare Disease Day 2024 webinar to join the discussion with clinical trial experts on a collaborative approach to patient-friendly trials in rare disease.

Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™

Retrieved on: 
Thursday, February 8, 2024

Once in the cell, Pombiliti can be properly processed into its most active and mature form to break down glycogen.

Key Points: 
  • Once in the cell, Pombiliti can be properly processed into its most active and mature form to break down glycogen.
  • Late-onset Pompe disease is a rare, debilitating, and life-threatening lysosomal disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA).
  • This is the second WORLDSymposium™ New Treatment Award presented to Amicus.
  • Amicus received the award in 2017 for the first and only oral therapy approved for people living with Fabry disease.

Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024

Retrieved on: 
Thursday, February 1, 2024

PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and 11 posters across its development programs will be included at the 20th Annual WORLDSymposium™ 2024 , being held February 4-9, 2024 in San Diego, CA.

Key Points: 
  • PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and 11 posters across its development programs will be included at the 20th Annual WORLDSymposium™ 2024 , being held February 4-9, 2024 in San Diego, CA.
  • Abstract Title: Multiorgan involvement in females with Fabry disease: Results from two Phase III trials and the followME registry (Poster #246)
    Abstract Title: Prevalence of migalastat-amenable mutations in patients with Fabry disease from Brazil, Argentina and Colombia (Poster #262)
    Presenter: Juan Politei, MD, Foundation for the Study of Neurometabolic Diseases, Buenos Aires, Argentina
    Abstract Title: Treatment-related benefit and satisfaction in patients with Fabry disease: Insight into patients’ expectations and preferences from the SATIS-Fab study (Poster #189)
    Presenter: Mark Roberts, MD, Salford Royal NHS Foundation Trust, Greater Manchester Neurosciences Centre, Manchester, U.K.
    Presenter: Benedikt Schoser, MD, Ludwig Maximilian University of Munich, Munich, Germany

Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook

Retrieved on: 
Sunday, January 7, 2024

PRINCETON, N.J., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided its preliminary and unaudited 2023 revenue, corporate updates, and full-year 2024 outlook.

Key Points: 
  • 2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year
    Successful Launches of Pombiliti™ + Opfolda™ Underway in the U.S., U.K., and Germany
    PRINCETON, N.J., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided its preliminary and unaudited 2023 revenue, corporate updates, and full-year 2024 outlook.
  • In 2023, Amicus met or exceeded its strategic priorities, highlighted by:
    Preliminary and Unaudited 2023 Revenue:
    Total revenue in 2023 reached ~$399.4 million, representing a year-over-year increase of 21%, reflecting strong operational growth measured at constant exchange rates (CER)1 of 20% and a favorable currency impact of approximately $2.7 million, or 1%.
  • Galafold (migalastat) net product sales in 2023 were ~$387.8 million, representing a year-over-year increase of 18%, or 17% at CER.
  • Full-year 2024 Galafold revenue guidance utilizes actual exchange rate as of December 31, 2023.

Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 3, 2024

PRINCETON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 8, 2024, at 2:15 p.m. PT.

Key Points: 

PRINCETON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 8, 2024, at 2:15 p.m. PT.

Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO

Retrieved on: 
Tuesday, December 5, 2023

PRINCETON, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Executive Chairman of Amicus Therapeutics, will step down from the Amicus Board of Directors and assume the role of President and Chief Executive Officer of BIO, the Biotechnology Innovation Organization, effective March 4, 2024. Michael Raab, Lead Independent Director, will become the Chairman of the Amicus Board of Directors. BIO is based in Washington, DC and is the world’s largest biotechnology policy and advocacy association, representing the entire biotechnology industry, with over 1,200 member organizations worldwide.

Key Points: 
  • PRINCETON, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Executive Chairman of Amicus Therapeutics, will step down from the Amicus Board of Directors and assume the role of President and Chief Executive Officer of BIO, the Biotechnology Innovation Organization, effective March 4, 2024.
  • Michael Raab, Lead Independent Director, will become the Chairman of the Amicus Board of Directors.
  • BIO is based in Washington, DC and is the world’s largest biotechnology policy and advocacy association, representing the entire biotechnology industry, with over 1,200 member organizations worldwide.
  • Mr. Crowley joined Amicus in 2005 and served as Chairman and Chief Executive Officer until 2022, when he transitioned to his current role as Executive Chairman.